2m 2m 2m 2m 2m 2m 2m
United Therapeut (UTHR)
NASDAQ
$544.19+$5.88 (+1.09%)
Price as of Jun 23, 2026 5:47 PM EDT- $22.8BMarket Cap
- 87.96%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
United Therapeut (UTHR)
$544.19+$5.88 (+1.09%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 3.2B +10.61% | 2.9B +23.63% | 2.3B +20.20% | 1.9B +14.88% | |
Cost of Revenue | 384.4M +24.12% | 309.7M +20.27% | 257.5M +69.85% | 151.6M +23.76% | |
Gross Profit | 1.1B -57.87% | 2.6B +24.04% | 2.1B +15.99% | 1.8B +14.18% | |
Sales and Marketing Expense | 755.8M +6.50% | 709.7M +48.75% | 477.1M N/A | N/A N/A | |
Research and Development Expense | -550.0M +14.35% | -481.0M +17.89% | -408.0M +26.35% | -322.9M -40.21% | |
Depreciation and Amortization Expense | 85.6M +18.07% | 72.5M +36.28% | 53.2M +3.70% | 51.3M +2.81% | |
Total Operating Expenses | 1.7B +12.65% | 1.5B +31.31% | 1.1B +19.44% | 956.6M -15.32% | |
Operating Profit | 1.5B +8.39% | 1.4B +16.21% | 1.2B +20.95% | 979.7M +76.24% | |
Interest Income | 192.0M -3.57% | 199.1M +22.37% | 162.7M +259.96% | 45.2M +170.66% | |
Interest Expense | N/A N/A | N/A N/A | -59.3M +83.02% | -32.4M +74.19% | |
Interest Income and Expense and Net | 192.0M -3.57% | 199.1M +92.55% | 103.4M +707.81% | 12.8M +773.68% | |
Total Nonoperating Income and Expense | 221.4M +36.67% | 162.0M +81.21% | 89.4M +407.22% | -29.1M -176.58% | |
Income before Taxes | 1.7B +11.36% | 1.5B +20.77% | 1.3B +34.05% | 950.6M +60.06% | |
Income Taxes | 379.2M +10.26% | 343.9M +18.79% | 289.5M +29.65% | 223.3M +89.08% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 1.3B +11.68% | 1.2B +21.35% | 984.8M +35.40% | 727.3M +52.86% | |
Net Income from Continuing Operations Applicable to Common | 1.7B +11.36% | 1.5B +20.77% | 1.3B +75.21% | 727.3M +52.86% | |
Basic EPS and Net Income | 30.13 +13.96% | 26.44 +25.67% | 21.04 +31.66% | 15.98 +50.75% | |
Diluted EPS and Net Income | 27.86 +13.07% | 24.64 +24.38% | 19.81 +32.07% | 15.00 +49.11% | |
Basic Weighted Average Shares | 44.3M -1.99% | 45.2M -3.42% | 46.8M +2.86% | 45.5M +1.34% | |
Diluted Weighted Average Shares | 47.9M -1.24% | 48.5M -2.41% | 49.7M +2.47% | 48.5M +2.54% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 1.6B -8.25% | 1.7B +40.53% | 1.2B +25.65% | 961.2M +7.42% | |
Short-Term Investments | 1.4B -13.16% | 1.6B -12.12% | 1.8B -4.85% | 1.9B +81.24% | |
Cash and Cash Equivalents and Short-Term Investments | 2.9B -10.61% | 3.3B +9.11% | 3.0B +5.47% | 2.8B +47.03% | |
Total Current Assets | 3.7B -4.42% | 3.9B +9.09% | 3.6B +5.05% | 3.4B +45.48% | |
Accumulated Depreciation | 567.8M +15.59% | 491.2M +14.71% | 428.2M +11.89% | 382.7M +11.77% | |
Property and Plant and Equipment and Net | 1.7B +41.50% | 1.2B +16.93% | 1.0B +21.35% | 861.5M +10.32% | |
Total Long-Term Assets | 196.9M -11.35% | 222.1M +46.31% | 151.8M +32.81% | 114.3M +5.64% | |
Total Assets | 7.9B +7.01% | 7.4B +2.75% | 7.2B +18.57% | 6.0B +16.94% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 0 -100.00% | 300.0M -25.00% | 400.0M N/A | N/A N/A | |
Total Current Liabilities | 560.6M -24.05% | 738.1M -8.24% | 804.4M +134.38% | 343.2M +12.38% | |
Total Long-Term Debt | 0 N/A | 0 -100.00% | 300.0M -62.50% | 800.0M 0.00% | |
Total Long-Term Liabilities | 223.2M +22.70% | 181.9M +133.80% | 77.8M -25.62% | 104.6M -0.19% | |
Total Liabilities | 783.8M -14.80% | 920.0M -22.18% | 1.2B -5.26% | 1.2B +3.11% | |
Retained Earnings | 8.6B +18.48% | 7.2B +19.83% | 6.0B +19.53% | 5.0B +16.86% | |
Total Stockholders Equity | 7.1B +10.12% | 6.4B +7.67% | 6.0B +24.77% | 4.8B +21.16% | |
Total Shares Outstanding | 43.6M -2.65% | 44.8M -4.70% | 47.0M +2.19% | 46.0M +2.05% | |
Cash Flow | |||||
Cash from Operating Activities | 1.6B +17.64% | 1.3B +35.70% | 978.0M +21.87% | 802.5M +34.15% | |
Capital Expenditures | 520.5M +111.16% | 246.5M +6.99% | 230.4M +65.99% | 138.8M +14.90% | |
Cash from Investing Activities | -551.3M -232.14% | 417.2M +157.98% | -719.6M -11.32% | -811.5M +66.67% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -1.1B -8.35% | -1.3B +10,444.54% | -11.9M -115.78% | 75.4M +68.30% | |
Financials Ratio | |||||
Gross Margin | 87.92% -1.47% | 89.24% +0.34% | 88.94% -3.51% | 92.17% -0.61% | |
Operating Margin | 46.89% -2.01% | 47.86% -6.00% | 50.91% +0.62% | 50.60% +53.41% | |
Return on Assets | 17.51% +6.46% | 16.45% +10.34% | 14.91% +14.93% | 12.97% +33.37% | |
Return on Equity | 19.71% +2.51% | 19.23% +5.27% | 18.27% +9.96% | 16.61% +28.39% | |
Revenue Growth | 10.61% -55.09% | 23.63% +16.94% | 20.20% +35.78% | 14.88% +9.16% | |
Current Ratio | 6.60 +25.84% | 5.25 +18.89% | 4.41 -55.18% | 9.85 +29.45% | |
Cash Ratio | 2.78 +20.80% | 2.30 +53.15% | 1.50 -46.39% | 2.80 -4.41% | |
Debt-to-Equity Ratio | 0.00 -100.00% | 0.05 -60.17% | 0.12 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.00 -100.00% | 0.04 -58.34% | 0.10 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow